Key result
Nonfasting triglycerides were associated with increased CHD mortality over 33 years (HR 1.10; 95% CI 1.05-1.16), with metabolic risk factors showing stronger effects at lower cholesterol levels.
Why the study?
Do conventional and metabolic risk factors predict CHD mortality across short, intermediate, and long periods of follow-up in middle-aged men?
Population
14,846 men aged 40-49 years from the Oslo Study prospective cohort
Design
Cohort
Follow-up
up to 33 years (1972-73 until 2006)
Authors
Loading...
Supports nonfasting triglycerides for long-term CHD risk stratification in men; hypothesis-generating and requires prospective confirmation.
Cohort (n=14,846)
Do conventional and metabolic risk factors predict CHD mortality across short, intermediate, and long periods of follow-up in middle-aged men?
Effect estimate: HR 1.10 (95% CI 1.05-1.16)
Conventional and metabolic risk factors, including nonfasting triglycerides, predict long-term CHD mortality, with metabolic variables showing stronger associations in men with lower total cholesterol levels.
Holme et al. (2011) conducted a cohort in Coronary heart disease (n=14,846). Conventional and metabolic risk factors was evaluated on CHD mortality associated with nonfasting triglycerides (0-33 years) (HR 1.10, 95% CI 1.05-1.16). Nonfasting triglycerides were associated with increased CHD mortality over 33 years (HR 1.10; 95% CI 1.05-1.16), with metabolic risk factors showing stronger effects at lower cholesterol levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: